IsoPSA, a New Biomarker Test, Differentiates High- and Low-Grade Prostate Cancer, Improves Diagnostic Accuracy

Urology Practice Management - October 2016, Vol 5, No 5 - Prostate Cancer
Wayne Kuznar

When combined with other clinically relevant parameters, the novel protein biomarker assay IsoPSA can improve the selection of patients with prostate cancer for biopsy.

The IsoPSA assay holds promise for improved diagnostic accuracy, said Eric A. Klein, MD, Chairman, Glickman Urological and Kidney Institute, Cleveland Clinic, OH, at the 2016 American Urological Association annual meeting.

In an ongoing multinational study comparing the clinical performance of the IsoPSA assay with that of serum prostate-specific antigen (PSA) measurement, “using IsoPSA reduced unnecessary biopsies by 52%, missed no high-grade cancers, and correctly identified 97% of low-risk patients,” said Dr Klein.

To be clinically useful, a biomarker must be specific to tissue type and to cancer type. The PSA measure is prostate-specific but not prostate cancer–specific, which limits its ability to distinguish between prostate cancer, prostatitis, benign prostatic hyperplasia, and urinary tract infection in an accurate way, Dr Klein explained.

The diagnostic accuracy, predictive value, and clinical utility of current biomarkers are limited by a lack of cancer specificity and by relatively poor sensitivity.

PSA has multiple structural isoforms that can be detected in the serum and that are cancer-specific. Current screening assays measure only the concentration of a limited number of prespecified isoforms. Conversely, the IsoPSA assay measures the concentration of all isoforms in an agnostic manner. “That’s important, because in different patients there may be different PSA isoforms that are associated with cancer that are not detectable by the current assays. Furthermore, there may be different isoforms of PSA in the same patient over the course of time that are also not captured by current assays,” Dr Klein said.

IsoPSA Test Reduces Unnecessary Biopsies by 52%

IsoPSA is a novel assay that uses aqueous-based solvents to detect overall changes in the structure or isoform mixtures of biomarkers.

The IsoPSA assay interrogates the entire PSA isoform distribution in serum, as opposed to preselecting individual protein biomarkers. “This is an add-on to standard total PSA or free PSA assays; it’s done very cheaply without requiring an additional blood draw. The way it will be reported…is the percent likelihood for an individual patient for the presence of Gleason 7 cancer,” said Dr Klein.

Preliminary studies showed excellent discrimination between cancerous and benign prostate diseases. The study presented at the meeting comprised 132 patients with PSA levels ranging from 2 ng/mL to 26 ng/mL. The objective was to assess the clinical performance (ie, ability to predict for Gleason score 7 cancer) of the IsoPSA assay against the standard PSA assay with a 12-core ultrasound-guided prostate biopsy.

Compared with PSA alone, which had an area under the curve (AUC) of 0.61 for prediction of Gleason score ≥7 cancer, adding IsoPSA to the model improved the AUC to 0.85.

The positive predictive value for aggressive cancer was very high, and the negative predictive value (negligible chance for aggressive cancer) was also very high, said Dr Klein.

In patients at very low risk for aggressive disease, the negative predictive value was 97%; conversely, in those at high risk for high-grade disease, the positive predictive value was 86%.

“So IsoPSA has a very high ability to correctly discriminate clinical outcome,” Dr Klein said. Using the IsoPSA assay in clinical practice would reduce unnecessary biopsies by 52%. In addition, no high-grade cancers would be missed, and 97% of low-risk patients would be correctly identified.

Related Items
Enzalutamide or Apalutamide Added to ADT Are 2 New Options for Hormone-Sensitive Prostate Cancer
Phoebe Starr
Web Exclusives published on August 6, 2019 in Prostate Cancer
Darolutamide, New Androgen Receptor Inhibitor, Extends Metastasis-Free Survival in High-Risk Prostate Cancer
Phoebe Starr
Web Exclusives published on June 3, 2019 in Prostate Cancer
Treat Your Patients as Customers by Meeting Their Expectations
Wayne Kuznar
Rheumatology Practice Management April 2018 Vol 6 No 2 published on April 16, 2018 in NORM Conference News
2017 HIPAA Updates and the Office for Civil Rights Audits
Wayne Kuznar
Rheumatology Practice Management October 2017 Vol 5 No 5 published on October 20, 2017 in NORM News
Rise in Metastatic Prostate Cancer Has Screening, Treatment Implications
Charles Bankhead
Urology Practice Management - December 2016, Vol 5, No 6 published on December 7, 2016 in Prostate Cancer
Promising Antitumor Activity of ODM-201 in Metastatic Prostate Cancer
Wayne Kuznar
Urology Practice Management - December 2016, Vol 5, No 6 published on December 7, 2016 in Prostate Cancer
Is the Glass Half Empty or Half Full? First Study Compares Robotic-Assisted Surgery and Open Radical Prostatectomy
Alice Goodman
Urology Practice Management - December 2016, Vol 5, No 6 published on December 7, 2016 in Prostate Cancer
Shorter Hypofractionated Therapy New Standard for Prostate Cancer
Phoebe Starr
Urology Practice Management - October 2016, Vol 5, No 5 published on October 10, 2016 in Prostate Cancer
Atezolizumab Could Be Start of “Seismic Shift” in Metastatic Bladder Cancer Therapy
Wayne Kuznar
Urology Practice Management - August 2016, Vol 5, No 4 published on August 15, 2016 in Bladder Cancer
Referring Radical Prostatectomies to High-Volume Providers Could Save Millions
Chase Doyle
Urology Practice Management - August 2016, Vol 5, No 4 published on August 15, 2016 in Prostate Cancer
Last modified: October 14, 2016
  • American Health and Drug Benefits
  • Lynx CME
  • Value Based Care in Rheumatology
  • Oncology Practice Management
  • Urology Practice Management